Risk of Treatment‐Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta‐analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR‐Mutated Non–Small Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2016.11.2236
Abstract: Introduction Gefitinib, erlotinib, and afatinib are tyrosine kinase inhibitors (TKIs) used for treatment of advanced EGFR‐mutated NSCLC. Estimating differences in toxicity between these EGFR TKIs is important for personalizing treatment. Methods We performed a meta‐analysis… read more here.
Keywords: gefitinib erlotinib; risk; egfr tkis; treatment ... See more keywords